Genetic Technologies Completes Two Genetic Risk Tests for Colorectal and Breast Cancer

Genetic Technologies (NASDAQ:GENE, ASX:GTG), has announced two new cancer risk assessments, branded ‘GeneType for Colorectal Cancer’ and ‘GeneType for Breast Cancer.’

As quoted in the press release:

GTG’s polygenic risk tests combine information from genetic markers called Single Nucleotide Polymorphisms to assess how people’s genetic make-up affects their risk of developing various diseases. GTG’s heavily patented approach to incorporating further clinical risk information places them at the forefront of the global risk assessment space.

The new breast cancer test provides substantial improvement over GTG’s legacy breast cancer test (which was called BREVAGenplus) by incorporating multiple additional clinical risk factors. This test will provide healthcare providers and their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer.

The world-first polygenic risk test for colorectal cancer provides healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal cancer.

Importantly, GTG’s new risk tests and the resulting detailed healthcare provider and patient reports empower those people at increased risk to make specific lifestyle changes to reduce their particular risks and improve ongoing early future disease detection.

GTG Chairman and Acting CEO Dr Paul Kasian said, “These tests allow Government Health Leaders to directly target future screening to the most high-risk patients, thereby massively reducing health system costs and providing much better outcomes for patients. GTG’s proactive approach to disease management has the potential to save both lives and money by allowing the earlier detection of disease and focusing the use of limited healthcare resources to those most in need.”

Click here to read the full press release.